III.

.						

Itakura G, Kobayashi Y, Nishimura S, Iwai H, Takano M, Iwanami A, Toyama Y, Okano H, Nakamura M.	Controlling immune rejection is a fail-safe system against potential tumorigenicity after human iPSC-derived neural stem cell transplantation.	PLoS One	10(2)	e0116413	2015
Itakura G, Kobayashi Y, Nishimura S, Iwai H, Takano M, Iwanami A, Toyama Y, Okano H, Nakamura M.	Control of the survival and growth of human glioblastoma grafted into the spinal cord of mice by taking advantage of immunorejection.	Cell Transplant			2014 (in press)
Qin Y, Fu M, Takahashi M, Iwanami A, Kuga D, Rao RG, Sudhakar D, Huang T, Kiyohara M, Torres K, Dillard C, Inagaki A, Kasahara N, Goodglick L, Braun J, Mischel PS, Gordon LK, Wadehra M.	Epithelial membrane protein-2 (EMP2) activates Src protein and is a novel therapeutic target for glioblastoma.	J Biol Chem.	289 (20)	13974-13985	2014

Matsuda T, Murao N, Katano Y, Juliandi B, Kohyama J, Akira S, Kawai T, Nakashima K.	TLR9 signaling in microglial attenuates seizure-induced aberrant neurogenesis in the adult hippocampus.	Nat Commun	6	6514	2015
Zhou Z, Kohda K, Ibata K, Kohyama J, Akamatsu W, Yuzaki M, Okano HJ, Sasaki E, Okano H.	Reprogramming non-human primate somatic cells into functional neuronal cells by defined factors.	Mol Brain	7	24	2014
Kondo T, Funayama M, Tsukita K, Hotta A, Yasuda A, Nori S, Kaneko S, Nakamura M, Takahashi R, Okano H, Yamanaka S, Inoue H.	Focal transplantation of human iPSC-derived glial-rich neural progenitors improves lifespan of ALS mice.	Stem Cell Reports	3(2)	242-249	2014
Nori S, Okada Y, Nishimura S, Sasaki T, Itakura G, Kobayashi Y, Renault-Mihara F, Shimizu A, Koya I, Yoshida R, Kudoh J, Koike M, Uchiyama Y, Ikeda E, Toyama Y, Nakamura M, Okano H.	Long-term safety issues of iPSC-based cell therapy in a spinal cord injury model: oncogenic transformation with epithelial-mesenchymal transition.	Stem Cell Reports	4(3)	360-373	2015

IV.